FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileImpediMed Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
IPD.AX
ImpediMed Limited Stock AnalysisComprehensive stock analysis for ImpediMed Limited (IPD.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisIPD.AX
IPD.AX
ImpediMed Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
IPD.AX
  1. Home
  2. Stocks
  3. ImpediMed Limited

ImpediMed Limited

🇦🇺IPD.AX•ASX

ImpediMed Limited

🇦🇺IPD.AX•ASX

Your view on IPD.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About ImpediMed Limited

Industry
Medical - Devices
Sector
Healthcare
CEO
Erik Anderson
Headquarters
5900 Pasteur Court, Carlsbad, CA, US
Industry
Medical - Devices
Sector
Healthcare
CEO
Erik Anderson
Headquarters
5900 Pasteur Court, Carlsbad, CA, US
Description

Operating as a medical software technology provider, ImpediMed Limited is responsible for the development, production, and global sales of bioimpedance spectroscopy (BIS) instruments and accompanying software solutions, serving markets in Australia, North America, and internationally.

Its product portfolio features SOZO, a non-invasive BIS device used for evaluating lymphedema and tracking fluid levels in heart failure patients.

Additionally, it offers the SFB7, a single-channel, tetrapolar BIS instrument for analyzing body composition in healthy individuals, and ImpediVET, another single-channel, tetrapolar BIS device specifically designed for veterinary applications to measure fluid status and tissue composition.

ImpediMed primarily sells its technology to hospitals and clinics. This Australian-headquartered firm, based in Pinkenba, was established in 1999.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for ImpediMed Limited. Starting points for ImpediMed Limited: EPS -AUD 0.01, beta 1.09 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for ImpediMed Limited. ImpediMed Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for ImpediMed Limited. Trailing twelve-month EPS for ImpediMed Limited stands at -AUD 0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 20, 2026 · AUD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Earnings Estimate

EPSCurrent QtrJun 2018Next QtrJun 2022Current YearFY Jun 2027Next YearFY Jun 2028
Avg. estimate−AUD 0.07−AUD 0.01−AUD 0.00−AUD 0.00
Low estimate−AUD 0.07−AUD 0.01−AUD 0.00−AUD 0.00
High estimate−AUD 0.07−AUD 0.01−AUD 0.00−AUD 0.00
No. of analysts4423
Year-ago EPS——−AUD 0.011—
Growth————

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrJun 2018Next QtrJun 2022Current YearFY Jun 2027Next YearFY Jun 2028
Avg. estimateAUD 6.09MAUD 22.50MAUD 19.20MAUD 25.18M
Low estimateAUD 4.75MAUD 18.33MAUD 18.75MAUD 23.73M
High estimateAUD 7.24MAUD 27.95MAUD 19.64MAUD 26.64M
No. of analysts4412
Year-ago revenue——AUD 14.61M—
Growth——+31.4%—

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for ImpediMed Limited. ImpediMed Limited has reported as a listed company since 2007. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold IPD.AX20 companies
Compare IPD.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
ATX.AXAmplia Therapeutics LimitedHealthcareBiotechnology—
CMP.AXCompumedics LimitedHealthcareMedical - Devices—
CYC.AXCyclopharm LimitedHealthcareMedical - Devices—
EYE.AXNova Eye Medical LimitedHealthcareMedical - Devices—
GSS.AXGenetic Signatures LimitedHealthcareMedical - Diagnostics & Research—
M7T.AXMach7 Technologies LimitedHealthcareMedical - Healthcare Information Services—
MVP.AXMedical Developments International LimitedHealthcareDrug Manufacturers - Specialty & Generic—
MX1.AXMicro-X LimitedHealthcareMedical - Devices—
More Medical - Devices companies
TickerTypeCompanySectorExchangeMkt cap
BIOBio-Rad Laboratories, Inc.HealthcareNYSE$10.0B
BIO-BBio-Rad Laboratories, Inc.HealthcareNYSE$9.6B
BJDXBluejay Diagnostics, Inc.HealthcareNASDAQ$2.0M
BMRABiomerica, Inc.HealthcareNASDAQ$5.0M
BRKRBruker CorporationHealthcareNASDAQ$9.7B
BRKRPBruker CorporationHealthcareNASDAQ$9.6B
BRNHFBroncus Holding CorporationHealthcareOTC$42.1M
BRSFBrain Scientific Inc.HealthcareOTC$124
BSXBoston Scientific CorporationHealthcareNYSE$63.3B
BTCYBiotricity, Inc.HealthcareOTC$7.7M
BVSBioventus Inc.HealthcareNASDAQ$727.2M
CALZFPolyNovo LimitedHealthcareOTC$472.9M
Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold ImpediMed Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for ImpediMed Limited. Coverage tracks ImpediMed Limited within Medical - Devices (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of ImpediMed Limited.

IPD.AX AnalysisWeak
Past
1
Growth
2
Health
3
Profit
1
Value
1

News

Latest Market News